Meeting
2016 Gastrointestinal Cancers Symposium
PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
Authors
Takayuki Yoshino
National Cancer Center Hospital East, Kashiwa, Japan
Takayuki Yoshino , Hiroyuki Uetake , Katsuya Tsuchihara , Kohei Shitara , Kentaro Yamazaki , Eiji Oki , Takeo Sato , Takeshi Naitoh , Yoshito Komatsu , Takeshi Kato , Kouji Iwasaki , Junpei Soeda , Masamitsu Hihara , Takeharu Yamanaka , Atsushi Ochiai , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02394795
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr TPS776)
DOI
10.1200/jco.2016.34.4_suppl.tps776
Abstract #
TPS776
Poster Bd #
O7
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
First Author: Kei Muro
Poster
2023 ASCO Breakthrough
First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with HER2 amplification (HER2amp+), RAS wild type (WT) metastatic colorectal cancer (mCRC) according to tumor sidedness.
First Author: Eiji Oki
Poster
2023 ASCO Annual Meeting
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.
First Author: Kathrin Heinrich
Poster
2016 Gastrointestinal Cancers Symposium
Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.
First Author: Wen-zhuo He